$8.64
+0.08 (+0.93%)
Open$8.58
Previous Close$8.56
Day High$8.81
Day Low$8.47
52W High$17.44
52W Low$6.01
Volume—
Avg Volume82.4K
Market Cap76.84M
P/E Ratio—
EPS$-16.51
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+68.3% upside
Current
$8.64
$8.64
Target
$14.54
$14.54
$12.76
$14.54 avg
$24.66
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.25M | 5.50M | 4.94M |
| Net Income | 1.19M | 1.50M | 1.15M |
| Profit Margin | 22.6% | 27.2% | 23.3% |
| EBITDA | 2.24M | 2.36M | 2.10M |
| Free Cash Flow | 844.4K | 896.3K | 789.1K |
| Rev Growth | +6.7% | -8.7% | -5.9% |
| Debt/Equity | 0.59 | 0.52 | 0.49 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |